These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18458278)

  • 1. Monitoring cholesterol levels: measurement error or true change?
    Glasziou PP; Irwig L; Heritier S; Simes RJ; Tonkin A;
    Ann Intern Med; 2008 May; 148(9):656-61. PubMed ID: 18458278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators.
    Stewart RA; Sharples KJ; North FM; Menkes DB; Baker J; Simes J
    Arch Intern Med; 2000 Nov; 160(20):3144-52. PubMed ID: 11074745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data.
    Bell KJ; Kirby A; Hayen A; Irwig L; Glasziou P
    BMJ; 2011 Jan; 342():d12. PubMed ID: 21257657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which lipid measurement should we monitor? An analysis of the LIPID study.
    Glasziou PP; Irwig L; Kirby AC; Tonkin AM; Simes RJ
    BMJ Open; 2014 Feb; 4(2):e003512. PubMed ID: 24561494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico).
    Ital Heart J; 2000 Dec; 1(12):810-20. PubMed ID: 11302109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.
    Morris R; Robinson G; Tilyard M; Gurr E
    N Z Med J; 1996 Aug; 109(1028):319-22. PubMed ID: 8816723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
    Lewis SJ; Moye LA; Sacks FM; Johnstone DE; Timmis G; Mitchell J; Limacher M; Kell S; Glasser SP; Grant J; Davis BR; Pfeffer MA; Braunwald E
    Ann Intern Med; 1998 Nov; 129(9):681-9. PubMed ID: 9841599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"].
    Scheen AJ
    Rev Med Liege; 1999 Jan; 54(1):2-3. PubMed ID: 10081301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Group for Cardiac Risk Patients].
    Fortschr Med; 1994 Feb; 112(5):57-64. PubMed ID: 8163252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
    Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
    J Atheroscler Thromb; 1996; 3(2):95-104. PubMed ID: 9226461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
    Scheen AJ; Kulbertus H
    Rev Med Liege; 2004 Mar; 59(3):167-73. PubMed ID: 15139406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.